SCHEMBL288796

SCHEMBL288796

CCN(CC)C(=O)c1ccccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.62
HSP90AA1 P07900 4/20 0.56
HSP90AB1 P08238 4/20 0.56
TP53 P04637 1/20 0.55
KEAP1 Q14145 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
HMGB1 P09429 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478348 1.00 TSHR (0.62) TSHRHSP90AA1HSP90AB1TP53KEAP1
Alcohol SCHEMBL28109153 0.96 TSHR (0.59) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL266244 0.88 TSHR (0.58) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL29822323 0.87 TP53 (0.69) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL610480 0.87 TP53 (0.69) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL10146384 0.86 TSHR (0.53) TSHRHSP90AA1HSP90AB1TP53KEAP1
SCHEMBL6371982 0.82 KDM4E (0.64) TSHRTP53KEAP1MAPK1ALDH1A1
SCHEMBL30337088 0.82 TP53 (0.62) TSHRTP53TDP1ALDH1A1HPGD
SCHEMBL28972723 0.82 TP53 (0.62) TSHRTP53TDP1ALDH1A1HPGD
SCHEMBL150008 0.80 TSHR (0.75) TSHRTP53KEAP1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066407-B2 Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (US) 2021-07-20 US claimed
US-20200331904-A1 3-AMINO-[1,2,4]-TRIAZOLE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-10-22 US claimed
EP-3720853-A1 3-AMINO-[1,2,4]-TRIAZOLE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH Bayer CropScience Aktiengesellschaft (DE) 2020-10-14 EP claimed
CN-111448194-A 3-amino- [1,2, 4] -triazole derivatives and their use for controlling undesired vegetation 拜耳作物科学股份公司 2020-07-24 CN claimed
US-20200115380-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2020-04-16 US claimed
US-10597395-B2 Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (US) 2020-03-24 US claimed
CN-110092778-A A method of using cheap metal copper for vilazodone intermediate and vilazodone drug 浙江工业大学 2019-08-06 CN claimed
US-20190218219-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2019-07-18 US claimed
CN-109970705-A A method of it is standby according to piperazine azoles intermediate and according to a piperazine azoles using cheap metal copper 浙江工业大学 2019-07-05 CN claimed
WO-2019110398-A1 3-AMINO-[1,2,4]-TRIAZOLE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-06-13 WO claimed
US-20050215794-A1 Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-09-29 US claimed
US-6867298-B2 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2005-03-15 US claimed
US-20040204412-A1 Phenylglycine derivatives useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
WO-2004072101-A2 PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-26 WO claimed
CN-1518534-A Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation 麻省理工学院 2004-08-04 CN claimed
US-6759554-B2 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-07-06 US claimed
EP-1390340-A1 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2004-02-25 EP claimed
US-20040019216-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-01-29 US claimed
US-20030065187-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-04-03 US claimed
WO-2002085838-A1 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218219-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS CYCS, HCCS, IDH3B TSHR 3293/4885HSP90AA1 3213/4885HSP90AB1 3249/4885
US-20050215794-A1 Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds CBR3, ADH5, IDH1 TSHR 3230/4885HSP90AA1 3261/4885HSP90AB1 3709/4885
US-20040204412-A1 Phenylglycine derivatives useful as serine protease inhibitors F7, SERPINE1, HABP2 TSHR 1647/4885HSP90AA1 2786/4885HSP90AB1 3372/4885
US-20200331904-A1 3-AMINO-[1,2,4]-TRIAZOLE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH NAT1, AGXT, CYP4Z1 TSHR 851/4885HSP90AA1 1779/4885HSP90AB1 1866/4885
US-10597395-B2 Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof CYP3A7, CYP4B1, CYP1B1 TSHR 2852/4885HSP90AA1 4345/4885HSP90AB1 4007/4885
US-20030065187-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds ADH5, CBR3, ALDH3A1 TSHR 3079/4885HSP90AA1 3140/4885HSP90AB1 3649/4885
US-20040019216-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds ADH5, CBR3, ALDH3A1 TSHR 3079/4885HSP90AA1 3140/4885HSP90AB1 3649/4885
US-11066407-B2 Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof CYP2F1, CYP3A4, CYP4F2 TSHR 2718/4885HSP90AA1 4616/4885HSP90AB1 4546/4885
US-20200115380-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS HCCS, CYCS, CBR3 TSHR 3274/4885HSP90AA1 3072/4885HSP90AB1 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.